Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference

Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.

Rhea-AI Summary

Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.

The company’s CFO, Hans Jeppsson, is scheduled to present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. Vicore’s lead program, buloxibutid, an oral ATRAG for idiopathic pulmonary fibrosis, holds FDA Orphan Drug and Fast Track designations and is being studied in the 52-week Phase 2b ASPIRE trial.

Argus Aug 26 session

-1.48% close to close Open Argus

Details

News Market Reaction – VCRE

On Aug 26, the day this news came out, VCRE closed 1.48% below the previous close.

Data tracked by StockTitan Argus for the Aug 26 session.

Key Figures

Conference edition: 17th annual Presentation date: September 2, 2026 Presentation time: 14:25-14:45 CEST +3 more

Conference edition

17th annual

Pareto Securities Healthcare Conference

Presentation date

September 2, 2026

Pareto Securities Healthcare Conference

Presentation time

14:25-14:45 CEST

September 2, 2026 presentation

Investor meetings

1×1 meetings

Conference participation format

Trial duration

52-week

ASPIRE trial

Trial phase

Phase 2b

Global ASPIRE trial in IPF

Historical Context

2 past events · Latest: Aug 24

2 events

1. Aug 24

   Conference presentation

   24h Move

   -8.0%

   Conference participation preceded a negative 24-hour stock reaction.

2. Jul 07

   Investor forum

   24h Move

   -7.5%

   Forum participation preceded a negative 24-hour stock reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

orphan drug, fast track designation, phase 2b, ipf

4 terms

orphan drug regulatory

"received Orphan Drug and Fast Track designation"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track designation regulatory

"Orphan Drug and Fast Track designation from the United States Food"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

phase 2b medical

"global 52-week Phase 2b ASPIRE trial in IPF"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

ipf medical

"Phase 2b ASPIRE trial in IPF"

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / August 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Pareto Securities 17th Annual Healthcare Conference in Stockholm.

Location: Hotel At Six, Stockholm, Sweden
Format: Presentation and 1×1 meetings
Presentation Date and Time: Wednesday, September 2, 2026, 14:25-14:45 CEST
Participant: Hans Jeppsson, Chief Financial Officer

For more information, please contact:
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Present at the Pareto Securities 17th Annual Healthcare Conference

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Vicore Pharma (VCRE) present at the Pareto Securities 17th Annual Healthcare Conference?

Vicore Pharma will present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. According to Vicore Pharma, the session will take place during the Pareto Securities 17th Annual Healthcare Conference held at Hotel At Six in Stockholm, Sweden.

Who will represent Vicore Pharma (VCRE) at the Pareto Securities Healthcare Conference 2026?

Vicore Pharma will be represented by Hans Jeppsson, the company’s Chief Financial Officer. According to Vicore Pharma, he will deliver the presentation and participate in 1×1 meetings during the Pareto Securities 17th Annual Healthcare Conference in Stockholm, Sweden.

Where is the Pareto Securities 17th Annual Healthcare Conference featuring Vicore Pharma (VCRE) being held?

The conference featuring Vicore Pharma is being held at Hotel At Six in Stockholm, Sweden. According to Vicore Pharma, the company will give a presentation and hold 1×1 investor meetings at this venue on September 2, 2026.

What format will Vicore Pharma’s (VCRE) participation at the Pareto Securities Healthcare Conference take?

Vicore Pharma’s participation will include a formal presentation and 1×1 meetings. According to Vicore Pharma, the presentation is scheduled for September 2, 2026, 14:25–14:45 CEST, followed by the opportunity for individual investor or stakeholder discussions.

What is Vicore Pharma’s (VCRE) lead program buloxibutid mentioned in the conference announcement?

Buloxibutid is Vicore Pharma’s lead oral small molecule angiotensin II type 2 receptor agonist. According to Vicore Pharma, it targets idiopathic pulmonary fibrosis, has Orphan Drug and Fast Track designations from the FDA, and is being evaluated in the global 52-week Phase 2b ASPIRE trial.

What therapeutic areas is Vicore Pharma (VCRE) focusing on as a clinical-stage company?

Vicore Pharma focuses on respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). According to Vicore Pharma, the company develops a novel class of drugs called angiotensin II type 2 receptor agonists (ATRAGs) with potential disease-modifying effects in these indications.